These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 24064478

  • 1. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.
    Ohta A, Kato H, Murayama K, Hashimoto E, Murakami M, Nishine A, Ohshige T, Sada Y, Asai S, Kawata T, Nagai Y, Katabami T, Tanaka Y.
    Endocr J; 2014; 61(1):13-8. PubMed ID: 24064478
    [Abstract] [Full Text] [Related]

  • 2. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S, Ohta A, Kato H, Sada Y, Nagai Y, Kondo A, Sasaoka T, Tanaka Y.
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.
    Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, Hanefeld M.
    Acta Diabetol; 2013 Aug; 50(4):587-95. PubMed ID: 23430192
    [Abstract] [Full Text] [Related]

  • 5. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC, BETA study group.
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [Abstract] [Full Text] [Related]

  • 6. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.
    Pscherer S, Larbig M, von Stritsky B, Pfützner A, Forst T.
    J Diabetes Sci Technol; 2012 May 01; 6(3):634-40. PubMed ID: 22768894
    [Abstract] [Full Text] [Related]

  • 11. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B, Zhao J, Yang W, Lantus Registry Study Group.
    Diabetes Metab Res Rev; 2017 Mar 01; 33(3):. PubMed ID: 27667797
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
    Schiel R, Müller UA.
    Exp Clin Endocrinol Diabetes; 2007 Nov 01; 115(10):627-33. PubMed ID: 18058596
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
    Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB.
    Diabetes Care; 2018 Oct 01; 41(10):2147-2154. PubMed ID: 30104294
    [Abstract] [Full Text] [Related]

  • 17. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug 01; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR, Traylor L, Dain MP, Landgraf W.
    Diabetes Res Clin Pract; 2014 Nov 01; 106(2):264-74. PubMed ID: 25195151
    [Abstract] [Full Text] [Related]

  • 19. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA, Baron MA, Gao L, Blonde L.
    Postgrad Med; 2014 May 01; 126(3):111-25. PubMed ID: 24918797
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.